Enterprise Mindray's IPO Rose 44% | Market capitalisation is expected to impact | ' Gem one brother '
Medical Network October 17 News October 16, Mai Rui Medical in the Shenzhen Exchange listed transactions, officially landed gem. As a member of the China-share privatization comeback, the 2015-year-old Swiss medical service has been retired from the NYSE.
Now, finally, return to the domestic capital market. The IPO, Mai Rui Medical Public issue 122 million shares, the IPO price of 48.80 yuan/share, raise the total capital of 5.93 billion yuan, for Business
The largest ever IPO in the history of Ningde, the record of the 5.462 billion yuan that was set by the era.
The first day of the IPO rose 44%
Mindray Medical, established in 1999, landed in the NYSE in 2006, and in 2015 as a member of the mid-share privatization comeback, the Swiss medical company retreated from the NYSE.
On the morning of October 16, Shenzhen deputy Mayor Wang Lixin, Mai Rui Medical chairman Lee Sitin, Mai Rui Medical President Chengming and other attended the company's IPO ceremony held in Shenzhen, Mai Rui Medical hundred staff representatives also to the scene for the company. After the opening, the company's share price rose 20%, the price of 58.56 yuan per share.
Later on the plate, after the resumption of licensing, Mai Rui Medical Rapid seal in trading, as of the close, the company's share price rose 44%, reported to close at 70.27 yuan/share, the total market value of 85.427 billion yuan. Previously, there was a general expectation that Mindray could reach a market value of $130 billion to $150 billion. According to analysis, the current A-share Medical devices
Industry average 50 times times the price-to-earnings calculation, after the Swiss medical listing, is expected to become after the Ningde era and delivered genre shares, the third to enter the billion dollar market value of the club's gem company, and if it can harvest 4 consecutive trading, Mai Rui Medical market value or will surpass the Ningde era, become the Gem market value ' a brother '.
First half venture board most profitable company Mindray specializes in the development, manufacturing and marketing of medical devices.
The company was listed on the NYSE in 2006 and retired from the United States in 2015 after 10 years of listing. Benefiting from the continued steady growth of the medical device market and the company's competitive advantage in research, development, production and marketing, in the first half of 2018, Mai Rui medical revenue of 6.808 billion yuan, an increase of 24.35%; Achieve net profit of 1.872 billion yuan, up 55.25% yoy;
To achieve the net profit deduction of 1.842 billion yuan, up 50.48% yoy. According to relevant data, the first half of 2018, GEM listed companies net profit of more than 1 billion yuan only two, respectively, the light media 2.107 billion yuan and three environmental protection 1.214 billion yuan.
But from the first half of 2018 the deduction of non-net profit, Mai Rui Medical in the gem ranked first. In addition, according to the company's announcement in the listing notice of the first three quarterly results of the forecast, January 2018-September, the company estimated operating income of $10.1 billion to $10.45 billion, a year earlier than the same period increased by 21.03% to 25.23%; The net profit attributable to shareholders of the parent company is expected to be $2.8 billion to $3 billion, representing an increase of 40.42% to 50.45% over a year earlier;
The net profit attributable to the parent company's shareholders after deduction of non-recurrent gains was estimated at $2.75 billion to $2.95 billion, representing an increase of 36.67% to 46.61% over a year earlier. Lee Sitin in the listing ceremony, said, ' Mindray Medical is not had been, we are still a very young company, we have a positive spirit, with tacit understanding of the management team, have the practical work, like-minded excellent staff, in the broad prospects of the medical equipment industry, we have 10,000 reasons to operate the company well!
' It is worth mentioning that the prospectus shows that Mai Rui Medical fund will be used to expand the bright production base, Nanjing Mindray Surgery Product Manufacturing Center construction, Mai Rui Nanjing Biological Reagent Manufacturing Center construction, research and development innovation Platform upgrade, Marketing service system upgrade, information system construction, repayment of bank loans and supplementary operating funds and other 7 projects
. Mindray said that in the future will continue to work to further reduce medical costs and improve research and development innovation capabilities, in order to maintain the company's products cost-effective advantage on the basis of actively facing the challenges of foreign competitors, and strive to become a world-class leading medical equipment.
